EPRX Stock — Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)

Updated October 16, 2026.

EPRX is a Stock. Total return is 124.4% over the past 2.5 years, 72.8 points ahead of SPY at 51.6%.

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing drug-delivery products for therapeutic areas with unmet medical needs, including treatments for knee osteoarthritis and eosinophilic esophagitis using its proprietary Diffusosphere technology platform. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage biotech development with higher risk and growth potential rather than income.

EPRX performance versus SPY

Price and return data through 2026-10-16.

Total return is 124.4% over the past 2.5 years, 72.8 points ahead of SPY at 51.6%. Over the past year its total return — price change plus distributions reinvested — is 12.8%. Its deepest 1-year drawdown was 35.9%.

EPRX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/05/2024

Distribution frequency

None

Last close

$6.62 (as of 2026-10-16)

Market cap

$437,405,729

Average volume

582306.0

Beta

1.215

Payout ratio

0.0%

EPS

$-0.99

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EPRX risks and drawbacks

The deepest 1-year drawdown on record here is 35.9%.

Who may consider EPRX — and who may not

It is a weaker fit for investors who need monthly cash flow (EPRX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on EPRX

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions